LABCORP  and non-profit organisation MD Anderson Cancer Center Foundation Spain have entered a strategic collaboration to boost access to early phase clinical trials in oncology.

Under this partnership, Labcorp Drug Development will manage the oncology trials, which will be prioritised and carried out at MD Anderson Cancer Center Foundation Spain, offering a new model for trials in the future.

Initial-stage trials of experimental cancer therapies, often called Phase I or Phase Ib trials, are intended to detect the safety profile, dosing schedule, recommended dose and pharmacologic behaviour of new drugs or new combinations of therapies.

Labcorp senior vice-president and oncology head Prasanth Reddy said: “This collaboration will help accelerate the discovery and development of cancer therapies worldwide. 

“Early phase clinical research in people with cancer is the first step in the regulatory approval process for new therapies, and this collaboration meets the growing demand for oncology clinical trials throughout Spain.”

The researchers at MD Anderson Cancer Center Foundation Spain focus on designing and developing trials to detect the best approaches for cancer prevention, diagnosis and treatment. 

Cancer centres that carry out these kinds of trials can offer more potential therapy options for patients.

In October last year, the Phase I Clinical Trials Unit in Madrid, Spain, was founded as the MD Anderson Cancer Center in Houston, Texas subsidiary. 

Devoted to Phase I trials in Spain, the new unit staffs skilled personnel in a bid to provide innovative therapies in a unified, multidisciplinary facility.

Labcorp Drug Development provides end-to-end expertise in oncology from research and discovery to marketing. 

In June this year, the company entered a new collaboration with HealthVerity to enhance its end-to-end drug development and clinical trial programmes.